Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial

• DOI: 10.1038/s41467-025-57774-x
• Publication Date: 2025-03-10T19:57:36Z
• Authors: Hui-Sheng Chen; Zi-Ai Zhao; Xin-Yu Shen; Si-Qi Qiu; Yu Cui; Jing Qiu; Wei Li; Hong Zhang; Wen-Huo Chen; Li-Hua Wang; De-Hui Zhang; Ying Chen; Yu-Tong Ma; Zong-En Gao; Shou-Chun Wang; Di Li; Hua Liu; Thanh N. Nguyen
• Keywords: Edaravone; Stroke

(This) phase II, randomized, double blinded, multi-center study aims to explore whether intravenous edaravone dexborneol (ED) could improve clinical outcomes in patients with anterior circulation stroke with successful endovascular reperfusion (ClinicalTrials.gov: NCT04667637().) Eligible patients were randomly (1:1) assigned into ED, which received intravenous ED (37.5 mg, 2/day, for 12 days) or control group, which received placebo. The primary endpoint was favorable functional outcome (a modified Rankin Scale [mRS] of 0–2 at 90 days). Two hundred patients were enrolled, including 97 in ED group and 103 in control group. The proportion of patients with 90-day mRS (0–2) was 58.7% (54/92) in ED group and 52.1% (49/94) in control group (unadjusted odds ratio 1.37, [95% CI 0.76-2.44], P = 0.29). This work suggests that intravenous ED is safe, but do not statistically improve 90-day functional outcomes in patients with anterior circulation stroke with successful endovascular reperfusion.